Victory Capital Management’s TG Therapeutics TGTX Stock Holding History

Victory Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.69M	Sell	85,297 -62,678	-42%	-$2.57M	﹤0.01%	1383
2026 Q1	$4.92M	Buy	147,975 +22,245	+18%	+$663K	﹤0.01%	1335
2025 Q4	$3.75M	Sell	125,730 -27,048	-18%	-$883K	﹤0.01%	1407
2025 Q3	$5.52M	Buy	152,778 +46,795	+44%	+$1.54M	﹤0.01%	1310
2025 Q2	$3.81M	Buy	105,983 +13,902	+15%	+$518K	﹤0.01%	1397
2025 Q1	$3.63M	Buy	92,081 +38,047	+70%	+$1.28M	﹤0.01%	1377
2024 Q4	$1.63M	Buy	54,034 +21,355	+65%	+$613K	﹤0.01%	1587
2024 Q3	$764K	Buy	32,679 +6,467	+25%	+$141K	﹤0.01%	1882
2024 Q2	$466K	Buy	26,212 +5,169	+25%	+$82.5K	﹤0.01%	1999
2024 Q1	$320K	Buy	21,043 +2,521	+14%	+$40.2K	﹤0.01%	2102
2023 Q4	$316K	Buy	18,522 +3,424	+23%	+$39.8K	﹤0.01%	2109
2023 Q3	$126K	Sell	15,098 -688,267	-98%	-$9.6M	﹤0.01%	2272
2023 Q2	$17.5M	Buy	703,365 +688,219	+4,544%	+$17.8M	0.02%	828
2023 Q1	$228K	Sell	15,146 -22	-0.1%	-$334	﹤0.01%	2216
2022 Q4	$179K	Sell	15,168 -27,265	-64%	-$198K	﹤0.01%	2285
2022 Q3	$251K	Buy	42,433 +15,174	+56%	+$99.5K	﹤0.01%	2303
2022 Q2	$116K	Hold	27,259	–	–	﹤0.01%	2444
2022 Q1	$189K	Hold	27,259	–	–	﹤0.01%	2417
2021 Q4	$518K	Sell	27,259 -377,757	-93%	-$9.81M	﹤0.01%	2137
2021 Q3	$13.5M	Sell	405,016 -20,547	-5%	-$636K	0.01%	1013
2021 Q2	$16.5M	Sell	425,563 -21,024	-5%	-$826K	0.02%	965
2021 Q1	$21.5M	Buy	446,587 +176,915	+66%	+$8.5M	0.02%	881
2020 Q4	$14M	Buy	269,672 +232,074	+617%	+$7.84M	0.02%	1018
2020 Q3	$1.01M	Sell	37,598 -16,024	-30%	-$369K	﹤0.01%	1701
2020 Q2	$1.04M	Hold	53,622	–	–	﹤0.01%	1713
2020 Q1	$528K	Sell	53,622 -2,997	-5%	-$37.9K	﹤0.01%	1822
2019 Q4	$628K	Hold	56,619	–	–	﹤0.01%	1912
2019 Q3	$318K	Buy	56,619 +54,500	+2,572%	+$380K	﹤0.01%	2055
2019 Q2	$18K	Hold	2,119	–	–	﹤0.01%	1795
2019 Q1	$17K	Hold	2,119	–	–	﹤0.01%	1749
2018 Q4	$9K	Hold	2,119	–	–	﹤0.01%	1770
2018 Q3	$12K	Buy	2,119 +278	+15%	+$3.18K	﹤0.01%	1779
2018 Q2	$24K	Hold	1,841	–	–	﹤0.01%	1788
2018 Q1	$26K	Sell	1,841 -1,215	-40%	-$15.5K	﹤0.01%	1780
2017 Q4	$25K	Hold	3,056	–	–	﹤0.01%	1779
2017 Q3	$36K	Hold	3,056	–	–	﹤0.01%	1757
2017 Q2	$31K	Buy	3,056 +1,078	+54%	+$12.1K	﹤0.01%	1755
2017 Q1	$23K	Hold	1,978	–	–	﹤0.01%	1765
2016 Q4	$9K	Buy	1,978 +111	+6%	+$651	﹤0.01%	1781
2016 Q3	$14K	Buy	1,867 +124	+7%	+$798	﹤0.01%	1765
2016 Q2	$11K	Buy	1,743 +274	+19%	+$2.23K	﹤0.01%	1620
2016 Q1	$13K	Buy	1,469 +116	+9%	+$1.01K	﹤0.01%	1638
2015 Q4	$16K	Buy	1,353 +75	+6%	+$947	﹤0.01%	1658
2015 Q3	$13K	Buy	1,278 +97	+8%	+$1.45K	﹤0.01%	1599
2015 Q2	$20K	Buy	+1,181	New	+$18.7K	﹤0.01%	1592

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Victory Capital Management's TGTX Position: Q2 2026 in Review

Victory Capital Management reduced its TG Therapeutics (TGTX) stake by 42% in Q2 2026, selling an estimated $2.57M and leaving 85,297 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

Victory Capital Management first reported a position in TGTX in Q2 2015 and has held it in 45 quarters since. The position peaked at $21.5M in Q1 2021. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Victory Capital Management held 85,297 shares of TG Therapeutics worth $4.69M as of Q2 2026.
Victory Capital Management sold 62,678 TG Therapeutics shares in Q2 2026, an estimated $2.57M.
TG Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1383 holding.
Victory Capital Management first reported a position in TG Therapeutics in Q2 2015 and has held it in 45 quarters since.
Victory Capital Management's TG Therapeutics position peaked at $21.5M in Q1 2021.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.